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Text Numerous diseases in humans are connected with the metabolism of iron. Indeed, on some estimates diseases related to iron affect more of the World’s population than any other disease. 
This is because iron deficiency affects over 30% of the world’s population1 and this can lead to anemia2. Often the lack of iron results from poor diet, though there are genetic defects that lead to iron 
deficiency, such as the rare disease iron-refractory iron deficiency anemia3. Too much iron can lead to iron-overload diseases4, which are often called hemochromatosis4. Again, such diseases can have a dietary origin as well as a genetic origin. Central to the problem 
of humans attaining the right levels of iron are some of its chemical properties. Importantly, iron can exist in different oxidation states. The most common ones in biology are the ferrous state (Fe2+) and the ferric state (Fe3+). The ability of iron to cycle between these states is an important feature of many of the biochemical pathways that require iron for their normal function but such cycling can also 
be detrimental if not controlled properly. The conversion of Fe2+ to Fe3+ requires an oxidant and the most common one in biology is dioxygen, O2, although hydrogen peroxide (H2O2), a natural by-
product of aerobic respiration, can also oxidize iron efficiently. The propensity of Fe2+ to react with these species underpins many of the problems with too much iron. Unlike the majority of normal biochemical pathways, uncontrolled reactions of Fe2+ with O2 can 
produce so-called ‘reactive oxygen species’ (ROS). ROS are much 
more reactive than O2 and lead readily to tissue damage by reacting with components of cells, such as proteins and membranes. While 
many tissues have mechanisms for eliminating ROS before they can 
do harm, these mechanisms can be overwhelmed by the amount of 
ROS produced in cases of iron-overload. Another potential problem with iron is that while Fe2+ is relatively soluble in water under physiological conditions, Fe3+ is highly insoluble. This leads to iron-
containing particles being deposited in tissues where iron-overload is present.
The database maintained by the National Organization for Rare 
Diseases (NORD)5 lists four rare diseases involving iron-overload. 
These are: African iron overload, Neonatal hemochromatosis, 
Infantile neuroaxonal dystrophy, and Pantothenate linase-
associated neurodegeneration. The first two have, at least in part, a genetic component that directly affects iron metabolism, whilst the 
genetic defects causing the latter two concern enzymes that have 
organic substrates but whose misbehavior leads to iron particles accumulating in the brain. It seems probable that there are other 
rare diseases involving iron not yet in the database as NORD state 
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that their database is not comprehensive. And as an 
illustration of this, iron-refractory iron deficiency anemia3 
is not in the NORD database. Because of the twin problems with iron of solubility and 
the formation of ROS, organisms throughout the animal, 
plant and microbial kingdoms have evolved an elegant means of storing iron that is not needed for immediate 
biochemical use in a soluble and non-toxic form. What they do is to deposit the iron within a protein shell6-9. The 
protein is ferritin, and this was the subject of our review9. 
Each molecule of ferritin can hold as many as 4,300 Fe3+ 
ions; it was the high iron content that led Laufberger10, who 
first described ferritin, to coin the name ferritin from the Latin ferratus, which means shod or furnished with iron. 
Since Laufberger’s publication10 there have been numerous 
original research papers and many excellent reviews published about it, such as references6-8. Our article9 took a 
different approach to many of these. Two widely held views 
in the ferritin field are that ferritins in the animal, plant and 
microbial kingdoms share a common evolutionary origin11, and that their primary function is as iron stores to protect 
the organism. However, it is clear that not all ferritins 
behave the same in in vitro assays and that many differ in the nature of the genetic control of their production. These 
observations underpinned our proposal that different 
ferritins have different primary functions9. An example of 
one such alternative function is the rapid removal of O2, in which ferritin acts as an antioxidant since deposition of Fe3+ within ferritin starts with Fe2+, which is used to reduce O2 to H2O at catalytic sites within the protein. A ferritin whose 
primary function is to rapidly remove O2 may experience 
different evolutionary pressures to one whose function is 
to rapidly sequester iron in a non-toxic form, or to rapidly release iron from its mineralized store.
A major topic in our review9 was how ferritin handles 
iron. This has been intensively studied for more than 70 years but, as we noted9, it is not known precisely how any ferritin accumulates iron, let alone releases it, and 
both are still major areas of activity. Whilst most in vitro 
studies of iron release do not involve damage to the 
protein component, in humans an intracellular degradative process, ferritinophagy12-14, directs ferritin to lysosomes where it is degraded, releasing iron to the cell. Whether 
there is a non-destructive release mechanism in humans as well is not certain but it is clear that in bacteria iron release from some ferritins occurs without damage to the protein component15,16. The elegant work of Theil and her colleagues17 with frog ferritin has provided a picture of iron uptake by this protein, but it is not clear how much of this holds for other ferritins. This mechanistic area is 
one of continuing debate, with a common view that we set 
out in our review9, that different ferritins accumulate iron 
by different mechanisms. However, a counter view is that there is a single mechanism that holds for all ferritins18.
Our review9 did not address directly the human health issues connected with iron metabolism but we did describe some studies19,20 on ferritins from patients suffering with 
beta-thalassemia and hemochromatosis. We noted9 that it was unclear whether the results of these studies can be extrapolated to ferritins from humans not suffering from 
such diseases since the flow of iron into ferritin is likely to 
be different under normal and iron-overload conditions. 
It is probable for the rare diseases in the NORD database5 
referred to above, and for the more common cases of severe 
iron-overload, that it is not the absolute amount of iron in 
a tissue that is the key factor, but the amount relative to the 
available storage capacity of ferritin.
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